Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology Conference
August 10 2021 - 7:00AM
Business Wire
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a
clinical stage precision medicine company developing innovative
treatments for genetically defined age-related macular degeneration
(AMD), today announced that Jason Meyeburg, Chief Executive Officer
of Gemini Therapeutics, is scheduled to participate virtually in
the H.C. Wainwright Ophthalmology Conference on Tuesday, August 17
at 9:00 AM ET.
A live webcast of the event will be available on the "Events
& Presentations" page on the Company's website. A replay of the
webcast will be archived on the Company's website for 30 days
following the presentation.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine
company developing novel therapeutic compounds to treat genetically
defined age-related macular degeneration (AMD). Gemini’s lead
candidate, GEM103, is a recombinant form of human complement factor
H protein (CFH) and is designed to address both complement
hyperactivity and restore retinal health in patients with AMD.
GEM103 is currently in a Phase 2a trial in dry AMD patients with a
CFH risk variant and a Phase 1/2a study in patients with
neovascular age-related macular degeneration with or at risk for
macular atrophy. Gemini has generated a rich pipeline including
recombinant proteins, gene therapies, and monoclonal antibodies and
is advancing a potentiating antibody for CFH, GEM307, into clinical
development for treatment of systemic diseases.
For more information, visit www.geminitherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210810005122/en/
Gemini Investor: Argot Partners Sherri Spear 212-600-1902
gemini@argotpartners.com
Gemini Media: Argot Partners Joshua Mansbach 212-600-1902
gemini@argotpartners.com
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gemini Therapeutics (NASDAQ:GMTX)
Historical Stock Chart
From Apr 2023 to Apr 2024